Hemanext

Hemanext is a private medical device company pioneering oxygen-controlled technology for red blood cell storage. Its core innovation, the Hemanext ONE® system, processes and stores RBCs in a low-oxygen (hypoxic) environment to mitigate storage lesions, thereby preserving cell viability and function closer to their natural state. The company targets two primary markets: improving care for chronically transfused patients (e.g., with sickle cell disease) and enhancing resuscitation outcomes in critical care/trauma. With a CMS reimbursement code established, Hemanext is positioned to commercialize its technology and redefine standards in transfusion medicine.

Oxygen-controlled processing and storage system for red blood cells (Hemanext ONE®). The platform removes and limits oxygen exposure during storage to reduce oxidative damage and preserve RBC viability, deformability, and metabolic function.

Hemanext's direct competition is limited, as it pioneers a new category of oxygen-controlled storage. However, it competes indirectly with the entire standard of care (conventional RBC storage in additive solutions). Other companies are exploring alternative storage methods (e.g., rejuvenation solutions, frozen storage) or pathogen reduction technologies that also aim to improve blood quality, but Hemanext's focus on hypoxia is distinct.